| Date | Time | Source | |
| 05/21/2013 | 9:30AM | PRNUS | "Modern Family" Star Julie Bowen Calls on Communities to Raise Their Hand for Anaphylaxis Awareness in Nationwide Competition
"Modern Family" Star Julie Bowen Calls on Communities to Raise Their Hand for Anaphylaxis Awareness in Nationwide Competition Total of $60,000 Will Be Awarded to School Districts In Educational Grants Recommended for Anaphylaxis Education PR Newswire BASKING RIDGE, N.J., May 21, 2013 BASKING RIDGE, N.J., May... More...>> |
| 05/21/2013 | 7:30AM | PRNUS | Federal Appellate Court Rules in Favor of Mylan in Patent Infringement Litigation Relating to Sunovion's Brovana® Product
Federal Appellate Court Rules in Favor of Mylan in Patent Infringement Litigation Relating to Sunovion's Brovana® Product PR Newswire PITTSBURGH, May 21, 2013 PITTSBURGH, May 21, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the Court of Appeals for the Federal Circuit has ruled in favor of Mylan... More...>> |
| 05/20/2013 | 10:55AM | DJN | 2nd UPDATE: Actavis to Buy Warner Chilcott For $5 Billion in Stock
--Actavis to swap 0.16 a share for each Warner Chilcott share --Warner Chilcott shareholders to own 23% of combined company --Actavis sees deal adding more than 30% to 2014 adjusted per-share earnings (Adds comments from Actavis CEO, other details throughout.) By Peter Loftus Drug maker Actavis Inc. (ACT) agreed to acquire... More...>> |
| 05/17/2013 | 7:30AM | PRNUS | Mylan Launches Generic Tricor® Tablets
Mylan Launches Generic Tricor® Tablets PR Newswire PITTSBURGH, May 17, 2013 PITTSBURGH, May 17, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg. Mylan Pharmaceuticals Inc. received final approval from the U.S... More...>> |
| 05/15/2013 | 7:00PM | DJN | Novartis Considers Possible Bid for Actavis
A heated takeover battle has erupted around generic-drug company Actavis Inc. (ACT) as industry players seek to shore themselves up amid increasing competition and fewer new knock-off-drug opportunities. Valeant Pharmaceuticals International Inc. (VRX, VRX.T) and Mylan Inc. (MYL) are evaluating their options after approaches... More...>> |
| 05/15/2013 | 11:40AM | PRNUS | Mylan Launches Generic Zomig® Tablets
Mylan Launches Generic Zomig® Tablets PR Newswire PITTSBURGH, May 15, 2013 PITTSBURGH, May 15, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application... More...>> |
| 05/10/2013 | 11:12AM | PRNUS | Presenting Sponsor Mylan Specialty L.P. Calls on Communities Nationwide to Join The Food Allergy Research & Education (FARE) ...
Presenting Sponsor Mylan Specialty L.P. Calls on Communities Nationwide to Join The Food Allergy Research & Education (FARE) Walk for Food Allergy More Than 65 Family-Friendly Walks Raise Food Allergy Awareness PR Newswire BASKING RIDGE, N.J., May 10, 2013 BASKING RIDGE, N.J., May 10, 2013 /PRNewswire/ -- In recognition... More...>> |
| 05/07/2013 | 4:27AM | ZACKS | Valeant Misses Earnings and Revenue Estimate in 1Q (Revised) - Analyst Blog
Valeant Pharmaceuticals’ (VRX) first quarter 2013 earnings of $1.27 (excluding special items but including stock-based compensation expense) were short of the Zacks Consensus Estimate by a penny but were up from the year-ago earnings of 1.08 per share. Revenues for the quarter were $1.07 billion, up 25% from the... More...>> |
| 05/03/2013 | 9:05AM | ZACKS | Valeant Beats Earnings, Misses Revs - Analyst Blog
Valeant Pharmaceuticals’ (VRX) first quarter 2013 earnings of $1.27 (excluding special items but including stock-based compensation expense) were short of the Zacks Consensus Estimate by a penny but were up from the year-ago earnings of 1.08 per share. Revenues for the quarter were $1.07 billion, up 25% from the... More...>> |
| 05/03/2013 | 3:55AM | ZACKS | Mylan Reports in line Earnings - Analyst Blog
Mylan, Inc.’s (MYL) first quarter 2013 earnings (excluding special items) of 62 cents per share were in line with the Zacks Consensus Estimate. Earnings increased 19% from the year-ago quarter. The year-over-year rise in earnings was primarily attributable to higher revenues. Adjusted earnings for first quarter 2013... More...>> |
| 05/02/2013 | 4:05PM | PRNUS | Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62
Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62 Reaffirms 2013 Adjusted Diluted EPS Guidance Range of $2.75 - $2.95 PR Newswire PITTSBURGH, May 2, 2013 PITTSBURGH, May 2, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three months ended March 31... More...>> |
| 04/30/2013 | 3:15PM | PRNUS | Deborah Autor, FDA's Deputy Commissioner for Global Regulatory Operations and Policy, to Join Mylan
Deborah Autor, FDA's Deputy Commissioner for Global Regulatory Operations and Policy, to Join Mylan PR Newswire PITTSBURGH, April 30, 2013 PITTSBURGH, April 30, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has appointed Deborah M. Autor as senior vice president, Strategic Global Quality and... More...>> |
| 04/26/2013 | 11:44AM | ZACKS | Orphan Drug Status for Teva/Xenon Drug - Analyst Blog
The US Food and Drug Administration (FDA) recently granted orphan drug designation to Teva Pharmaceutical Industries Ltd (TEVA) and Xenon Pharmaceuticals Inc. for their pain management candidate, XEN402. Orphan drug status was granted for the treatment of pain associated with erythromelalgia (EM). XEN402 is in a phase... More...>> |
| 04/25/2013 | 9:11AM | PRNUS | Mylan Specialty L.P. Announces 25th Anniversary Celebration of EpiPen® (epinephrine) Auto-Injector
Mylan Specialty L.P. Announces 25th Anniversary Celebration of EpiPen® (epinephrine) Auto-Injector Marketer of EpiPen® Auto-Injector, the No. 1 prescribed epinephrine auto-injector, announces additional efforts to increase anaphylaxis awareness, preparedness and access to treatment for those affected by life-threatening... More...>> |
| 04/22/2013 | 8:34AM | PRNUS | Mylan Announces $1 Million Gift to The Pittsburgh Promise Scholarship Fund
Mylan Announces $1 Million Gift to The Pittsburgh Promise Scholarship Fund Pledge Supports Campaign's Goal to Raise Additional $90 Million for Scholarships over Next Two Years PR Newswire PITTSBURGH, April 22, 2013 PITTSBURGH, April 22, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has contributed... More...>> |
| 04/19/2013 | 1:45PM | ZACKS | Favorable Court Ruling for Actavis - Analyst Blog
Actavis, Inc. (ACT) recently re-launched Vestura (3 mg drospirenone and 0.02 mg ethinyl estradiol), the company’s generic version of Bayer’s (BAYRY) oral contraceptive, Yaz. Actavis decided to re-launch Vestura following a favorable ruling by the US Court of Appeals for the Federal Circuit regarding the RE... More...>> |
| 04/19/2013 | 1:45PM | ZACKS | Favorable Court Ruling for Actavis - Analyst Blog
Actavis, Inc. (ACT) recently re-launched Vestura (3 mg drospirenone and 0.02 mg ethinyl estradiol), the company’s generic version of Bayer’s (BAYRY) oral contraceptive, Yaz. Actavis decided to re-launch Vestura following a favorable ruling by the US Court of Appeals for the Federal Circuit regarding the RE... More...>> |
| 04/18/2013 | 2:20PM | ZACKS | Data on Teva's Milprosa - Analyst Blog
Teva Pharmaceuticals (TEVA) recently announced new data from a phase III study on Milprosa (progesterone) vaginal ring which is being developed for luteal phase support in women undergoing in vitro fertilization (IVF). The data was from a sub-analysis of a phase III, single-blind, randomized study, which was conducted... More...>> |
| 04/15/2013 | 1:20PM | ZACKS | Still Neutral on Mylan - Analyst Blog
We are maintaining our Neutral recommendation on Mylan Inc. (MYL) with a target price of $30.00. Why the Reiteration? Mylan performed well in the fourth quarter of 2012. Mylan’s fourth quarter 2012 adjusted earnings of 65 cents per share beat the Zacks Consensus Estimate by a penny. The earnings beat was primarily... More...>> |
| 04/15/2013 | 1:20PM | ZACKS | Still Neutral on Mylan - Analyst Blog
We are maintaining our Neutral recommendation on Mylan Inc. (MYL) with a target price of $30.00. Why the Reiteration? Mylan performed well in the fourth quarter of 2012. Mylan’s fourth quarter 2012 adjusted earnings of 65 cents per share beat the Zacks Consensus Estimate by a penny. The earnings beat was primarily... More...>> |
